Multiple Myeloma in Relapse study: KLN-1010
Official title A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07075185
What this study is testing
What is KLN-1010?
KLN-1010 is an investigational medicine being studied as a potential treatment for relapsed or refractory multiple myeloma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to check if the treatment is safe and to find the best dose for future studies.
- Who it's for
- People with multiple myeloma that has returned or stopped responding to other treatments.
- What's involved
- Participants will receive the gene therapy and undergo medical tests to monitor their health and any side effects.
- Time commitment
- The source text does not specify the duration or visit schedule.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease
- Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and...
- Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1
- Participants must have acceptable laboratory values as defined by the protocol
You likely can't join if
- Participants must not have known central nervous system (CNS) involvement with myeloma
- Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin...
- Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy
- Participants cannot require systemic steroids for any condition
The study team makes the final eligibility decision.
Where it is enrolling
- Duarte, California, United States
- Palo Alto, California, United States
- San Francisco, California, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Boston, Massachusetts, United States
- Hackensack, New Jersey, United States
- Portland, Oregon, United States
- Camperdown, New South Wales, Australia
- Melbourne, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Duarte, California, United States; Palo Alto, California, United States; San Francisco, California, United States; Tampa, Florida, United States; Atlanta, Georgia, United States; Boston, Massachusetts, United States and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.